Crinetics Pharmaceuticals CRNX Business Segments — Other Research and Development Programs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:OtherResearchAndDevelopmentPrograms.
The official record: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — other research and development programs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — other research and development programs?
- Crinetics Pharmaceuticals (CRNX) reported business segments — other research and development programs of $8.33M in Q4 2025.
- How has Crinetics Pharmaceuticals's business segments — other research and development programs changed year-over-year?
- Crinetics Pharmaceuticals's business segments — other research and development programs increased by 28.1% year-over-year, from $6.5M to $8.33M.
- What is the long-term trend for Crinetics Pharmaceuticals's business segments — other research and development programs?
- Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's business segments — other research and development programs has grown at a 27.7% compound annual growth rate (CAGR), from $20.42M to $33.32M.
- What does business segments — other research and development programs mean?
- Aggregates the research and development expenditures for early-stage or secondary pipeline assets not specifically categorized under primary lead programs. This metric tracks the company's investment in diversifying its therapeutic portfolio and long-term innovation pipeline. It provides visibility into the breadth of the company's R&D efforts beyond its flagship clinical candidates.